LJMU Research Online

Li, L, Wang, C, Ye, Z, Van Spall, HGC, Zhang, J, Lip, GYH and Li, G

 Association Between Remnant Cholesterol and Risk of Incident Atrial Fibrillation: Population-Based Evidence From a Large-Scale Prospective Cohort Study

http://researchonline.ljmu.ac.uk/id/eprint/24077/

Article

For more information please contact researchonline@ljmu.ac.uk

ORIGINAL RESEARCH

Association Between Remnant Cholesterol and Risk of Incident Atrial Fibrillation: Population-Based Evidence From a Large-Scale Prospective Cohort Study

Likang Li , MPH; Chuangshi Wang , PhD; Zebing Ye, MD; Harriette G. C. Van Spall , MD, MPH; Jingyi Zhang, MPH; Gregory Y. H. Lip , MD*; Guowei Li , PhD, MMed, MBBS*

BACKGROUND: Evidence for the relationship between remnant cholesterol (RC) and incident atrial fibrillation (AF) risk remains sparse and limited.

METHODS AND RESULTS: Participants were enrolled between 2006 and 2010 and followed up to 2021. The multivariable Cox proportional hazards model was used to examine the relationship between RC quartiles and risk of incident AF. Subgroup analyses and sensitivity analyses were performed to explore the potential modification of the association and the robustness of the main findings. A total of 422 316 participants (mean age, 56 years; 54% women) were included for analyses. During a median follow-up of 11.9 years (first quartile–third quartile, 11.6–13.2 years), there were 24 774 AF events documented with an incidence of 4.92 events per 1000 person-years (95% CI, 4.86–4.98). Participants in higher RC quartiles had a lower risk of incident AF than those in the lowest quartile (first quartile): hazard ratio (HR)=0.96 (95% CI, 0.91–1.00) for second quartile; HR=0.92 (95% CI, 0.88–0.96) for third quartile; and HR=0.85 (95% CI, 0.81–0.89) for fourth quartile (P for trend <0.001). The association between RC quartiles and risk of incident AF was stronger in participants aged ≥65 years, in men, and in participants without history of diabetes when compared with control groups (P<0.001 for interaction).

CONCLUSIONS: On the basis of data from this large-scale prospective cohort study, elevated RC was associated with a lower risk of incident AF.

Key Words: atrial fibrillation ■ public health ■ remnant cholesterol

Atrial fibrillation (AF) is a common type of cardiac arrhythmia that significantly increases the risk of morbidity and mortality from stroke, heart failure (HF), and dementia.[1,2] Developing effective prevention strategies for AF remains an important global public health priority.[3] Focus has been directed toward previous studies that have identified various established risk factors for AF, such as age, sex, obesity, diabetes, and hypertension.[4,5] However, these established risk factors could only explain 50% to 60% of AF cases in the population, indicating the need to further explore potential novel risk factors.[6]

Dyslipidemia, a condition characterized by abnormal levels of cholesterol and triglycerides in the blood, is associated with an increased cardiovascular risk.[7] However, there is a "cholesterol paradox" that has been shown in AF, showing an inverse relationship between lipid levels and AF risk.[8–11] Many studies have

CLINICAL PERSPECTIVE

What Is New?

- The risk of incident atrial fibrillation was decreased with increased remnant cholesterol levels, with a 15% lower risk for the highest quartile compared with the lowest quartile.
- The association between remnant cholesterol quartiles and atrial fibrillation risk was modified by participants' status, including age, sex, and history of diabetes.

What Are the Clinical Implications?

- Our findings suggest that careful monitoring for incident atrial fibrillation would be needed when we introduce remnant cholesterol–lowering therapies.

Nonstandard Abbreviations and Acronyms

RC	remnant cholesterol
SCORE2	Systematic Coronary Risk Evaluation 2
TC	total cholesterol

---

explored the relationship between lipid levels and AF risk; some found no significant association,[12–14] whereas others reported a decreased risk.[11,15–20] A systematic review showed that higher levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were associated with a lower AF risk, but triglyceride levels were not.[10] However, these associations remain inadequately explained, warranting further evidence for exploration.

Remnant cholesterol (RC) is the cholesterol in triglyceride-rich lipoproteins, which includes very low-density lipoprotein cholesterol, intermediate-density lipoprotein cholesterol, and chylomicron remnants.[21] Studies have demonstrated that elevated RC levels increase the risks of atherosclerotic cardiovascular disease, myocardial infarction, HF, and mortality.[22–27] Although prevalence and severity of atherosclerosis have been associated with the risk of AF,[28,29] the role of RC as a risk factor for AF is less clear. Exploring the relationship between RC and AF risk may provide novel insights for risk assessment and management, and thus may help with AF prevention.

In this study, we aimed to explore the association of RC with incident AF risk in the general population using data from the UK Biobank, a large-scale prospective cohort study.

METHODS

The data can be available on application to the UK Biobank (www.ukbiobank.ac.uk/). Data described for the analyses and in the article will be made available on request.

Participants and Setting

From 2006 to 2010, the UK Biobank study enrolled >500 000 participants who were middle-aged or older from 22 assessment centers across England, Scotland, and Wales. They completed a touch-screen questionnaire, provided biological samples, and underwent physical measurements, as described in detail elsewhere.[30] All participants provided written informed consent for the research. The UK Biobank study was approved by the Research Ethics Committee (11/NW/0382).

For this study, we excluded participants with a history or baseline diagnosis of AF (n=6488) or who did not have information on lipid profiles (including TC, triglycerides, LDL-C, and HDL-C) (n=73 732). Finally, a total of 422 316 participants were included in this analysis (Figures S1–S6). To assess the potential selection bias, we used the standardized mean difference[31,32] to examine the balance of covariate distribution between the included participants and those excluded from analysis because of missing data on lipid profiles, where a standardized mean difference > 0.10 indicated difference in covariates between the 2 aforementioned groups. As shown in Tables S1–S6, all covariates showed balance between the 2 groups (standardized mean difference < 0.10). Therefore, there was no potential selection bias for this analysis.

Outcome Measures

The outcome of our study was the incidence of AF events during follow-up. AF incidence was identified using *International Classification of Diseases, Ninth Revision* (*ICD-9*), code 4273 and *International Classification of Diseases, Tenth Revision* (*ICD-10*), code I48. All participants were followed up from baseline until an AF diagnosis, death, or the censoring date (September 30, 2021, for England and Wales and October 31, 2021, for Scotland), whichever came first.

RC and Other Independent Variables

We measured triglycerides, TC, and HDL-C using the Beckman Coulter AU5800 analytical platform. Enzymatic analysis was used to assess triglycerides and TC, whereas enzyme immune-inhibition analysis was used to quantify HDL-C. We calculated LDL-C using the Friedewald equation when triglyceride was ≤4 mmol/L: LDL-C=TC−HDL-C−(triglycerides/2.2). When triglyceride

was >4 mmol/L, LDL-C was measured directly.[23,33,34] We calculated RC as TC minus LDL-C minus HDL-C, following the widely used and validated method by previous studies.[22,26,35]

We collected data on other independent variables at baseline, such as age, sex, race, education, body mass index, smoking status, alcohol consumption, physical activity (<600 or ≥600 metabolic equivalent of task min/wk), Townsend deprivation index (a higher index indicates greater deprivation), household income (low: <£18 000; medium: £18 000–£51 999; and high: ≥£52 000), Systematic Coronary Risk Evaluation 2 (SCORE2), comorbidities, medication, and supplementation intake. SCORE2 was calculated using the SCORE2 risk prediction algorithms for participants aged <70 years to predict future risk of cardiovascular disease.[36] For those aged ≥70 years, SCORE2 was calculated using SCORE2–Older Persons risk prediction algorithms.[37] Comorbidities included diabetes, hypertension, coronary artery disease (CAD), and HF. Medication and supplementation intake included antidiabetic drugs, antihypertensive drugs, statins, vitamins, and minerals. To minimize the potential underrecognition of baseline data on comorbidities and medication intake, we used a combination of information sources: patient self-reports, trained staff interviews, and *ICD-9* and *ICD-10* codes. We recorded the presence of this variable if the participant reported a positive response to any of the aforementioned data fields.

Statistical Analysis

We performed descriptive analysis for continuous variables with means±SDs and categorical variables with counts (percentages). We compared categorical and continuous variables across RC quartiles using χ^2 tests and ANOVAs, respectively.

The incidence rate of AF during follow-up was calculated, and its corresponding 95% CI was computed using the mid-P exact test.[38] We used the Cox proportional hazards model to assess the associations between the quartiles of RC and other lipid profiles with AF risk, taking the lowest quartile as reference group. The Cox models were adjusted for age, sex, race, body mass index, Townsend deprivation index, household income, physical activity, smoking and drinking, LDL-C, diabetes, hypertension, CAD, HF, antidiabetic and antihypertensive medications, and vitamin and mineral supplementation. Results were reported as hazard ratios (HRs) and their corresponding 95% CIs. We tested for linear trends across RC quartiles by including a variable with the median level of each quartile in the model, as widely used and validated by previous studies.[39–41] We also repeated the aforementioned multivariable analysis by treating RC as a continuous variable. There were no violations of the proportional

hazards assumptions. We used the g-computation (also known as direct standardization method)[42,43] to plot multivariable-adjusted cumulative incidence curves according to RC quartiles, taking all-cause death as a competing event for AF. The covariates we adjusted for were the same as those performed in the main analysis. A restricted cubic spline with 4 knots (5, 35, 65, and 95 percentiles) was used to evaluate nonlinear association between RC and AF risk.

We performed several subgroup analyses and added interaction terms to the adjusted model to explore the potential modification of the relationship between RC quartiles and AF risk. These included age (<65 or ≥65 years), sex (women or men), race (White or non-White [including Black, Asian, Mixed, and Other]), body mass index (<25 or ≥25 kg/m^2), smoking (no or yes), diabetes (no or yes), hypertension (no or yes), CAD (no or yes), HF (no or yes), statin use (no or yes), and LDL-C (<2.6 or ≥2.6 mmol/L). To test the robustness of the main findings, we conducted sensitivity analyses by (1) using the multiple imputation technique with 10 imputations to handle the missing data, (2) performing a competing risks analysis with all-cause death as a competing event for AF, (3) excluding individuals with postoperative AF, (4) excluding individuals with <5 years of follow-up to reduce potential reverse causation bias, and (5) excluding individuals with incident AF in the first 2 follow-up years. Another 2 sensitivity analyses were also conducted by (a) further adjusting for statin use and (b) adding SCORE2 to the adjustment model among participants who did not have cardiovascular disease and diabetes at baseline.[36]

We used SAS, version 9.4 (SAS Institute, Inc, Cary, NC), and R, version 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria), for all statistical analyses with a 2-sided significance level of 0.05.

RESULTS

This study included 422 316 participants with 5 034 664 person-years of follow-up. The mean±SD age of the participants was 56.46 (8.09) years, and 54% were women. The baseline characteristics of participants by the RC quartiles are shown in the Table. Participants in higher RC quartiles were older, more likely to be men, and had higher mean body mass index than those in lower RC quartiles. They were also more likely to have comorbidities (diabetes, hypertension, CAD, and HF) and take antidiabetic and antihypertensive medications, and statins. Figure S2 displays the density distribution of RC levels among the participants.

During a median follow-up of 11.9 years (first quartile–third quartile, 11.6–13.2 years), there were 24 774 AF events documented with an incidence of 4.92 events per 1000 person-years (95% CI, 4.86–4.98).

Table. Description of Baseline Characteristics for the Overall Participants and for the Groups by RC Quartiles

Characteristics	Total participants (n=422 316)	RC quartiles*			
		Quartile 1 (n=105 406)	Quartile 2 (n=105 762)	Quartile 3 (n=105 611)	Quartile 4 (n=105 537)
Age, mean±SD, y	56.46 ± 8.09	54.56 ± 8.33	56.75 ± 8.03	57.48 ± 7.83	57.06 ± 7.84
Women, n (%)	228 907 (54.20)	70 618 (67.00)	62 690 (59.27)	53 828 (50.97)	41 771 (39.58)
BMI, mean ±SD, kg/m^2	27.41 ± 4.77	25.24 ± 4.12	26.88 ± 4.57	28.20 ± 4.76	29.31 ± 4.62
White race, n (%)	397 818 (94.65)	97 764 (93.18)	99 871 (94.87)	100 108 (95.23)	100 075 (95.30)
With college or university degree, n (%)	136 703 (32.73)	40 119 (38.41)	34 927 (33.37)	31 857 (30.52)	29 800 (28.59)
Smoking status, n (%)					
Never	230 315 (54.81)	62 922 (59.96)	59 480 (56.50)	56 101 (53.41)	51 812 (49.37)
Previous	145 118 (34.54)	33 215 (31.65)	35 559 (33.78)	37 305 (35.51)	39 039 (37.20)
Current	44 748 (10.65)	8798 (8.38)	10 227 (9.72)	11 635 (11.08)	14 088 (13.42)
Alcohol intake status, n (%)					
Never	18 617 (4.42)	4176 (3.97)	4586 (4.35)	4901 (4.65)	4954 (4.71)
Previous	14 978 (3.56)	3310 (3.15)	3577 (3.39)	3880 (3.68)	4211 (4.00)
Current	387 661 (92.03)	97 649 (92.88)	97 365 (92.26)	96 565 (91.66)	96 082 (91.29)
Physical activity (≥600 MET min/wk), n (%)	277 321 (81.31)	73 376 (84.97)	70 577 (82.69)	67 837 (80.17)	65 531 (77.31)
TDI, mean SD	−1.31 ± 3.08	−1.33 ± 3.09	−1.39 ± 3.05	−1.34 ± 3.07	−1.19 ± 3.13
Household income, n (%)†					
High	93 426 (25.89)	28 406 (31.29)	23 498 (26.05)	21 046 (23.47)	20 476 (22.70)
Medium	185 747 (51.48)	45 891 (50.56)	46 720 (51.80)	46 674 (52.06)	46 462 (51.51)
Low	81 649 (22.63)	16 474 (18.15)	19 977 (22.15)	21 933 (24.46)	23 265 (25.79)
Lipid profiles, mean ±SD, mmol/L					
TC	5.70± 1.14	5.34 ± 1.01	5.62 ± 1.08	5.77 ± 1.13	6.08 ± 1.21
Triglycerides	1.75 ± 1.03	0.82 ± 0.16	1.26 ± 0.17	1.82 ± 0.40	3.09 ± 1.04
LDL-C	3.49 ± 0.97	3.28 ± 0.85	3.53 ± 0.93	3.59 ± 1.00	3.57 ± 1.07
HDL-C	1.45 ± 0.38	1.69 ± 0.40	1.52 ± 0.36	1.37 ± 0.32	1.22 ± 0.27
RC	0.76 ± 0.37	0.37 ± 0.07	0.57 ± 0.06	0.81 ± 0.08	1.29 ± 0.27
Comorbidity, n (%)					
Diabetes	21 380 (5.06)	3330 (3.16)	4247 (4.02)	6195 (5.87)	7608 (7.21)
Hypertension	114 419 (27.09)	19 675 (18.67)	26 523 (25.08)	32 374 (30.65)	35 847 (33.97)
CAD	17 674 (4.19)	3149 (2.99)	4153 (3.93)	4938 (4.68)	5434 (5.15)
HF	1314 (0.31)	210 (0.20)	295 (0.28)	344 (0.33)	465 (0.44)
Medication and supplementation intake, n (%)					
Antidiabetic drugs	15 640 (3.71)	2561 (2.43)	3080 (2.92)	4543 (4.31)	5456 (5.18)
Antihypertensive drugs	86 162 (20.43)	14 410 (13.69)	19 891 (18.83)	24 815 (23.53)	27 046 (25.66)
Statins	67 232 (15.92)	11 590 (11.00)	15 626 (14.77)	19 215 (18.19)	20 801 (19.71)
Vitamins	134 293 (31.96)	34 987 (33.34)	33 952 (32.25)	33 125 (31.54)	32 229 (30.73)
Minerals and other dietary supplementation	181 594 (43.13)	45 292 (43.09)	46 676 (44.25)	45 828 (43.53)	43 798 (41.64)

BMI indicates body mass index; CAD, coronary artery disease; HDL-C, high-density lipoprotein cholesterol; HF, heart failure; LDL-C, low-density lipoprotein cholesterol; MET, metabolic equivalent of task; RC, remnant cholesterol; TC, total cholesterol; and TDI, Townsend deprivation index.

*The cutoff points of the RC quartiles were 0.48, 0.67, and 0.97 mmol/L, respectively.

†A total of <£18 000, £18 000 to £51 999, and ≥£52 000 of average total household income before tax represented the low, medium, and high household income level, respectively.

There were 29 747 deaths during follow-up. Table S2 presents the specific causes of death and their corresponding numbers. Figure 1 shows the adjusted cumulative incidence of incident AF among RC quartile groups after taking all-cause death as a competing event. The association between RC quartiles and risk of incident AF is shown in Figure 2. Participants in higher RC quartiles had a lower risk of incident AF than those in the lowest quartile (first quartile): HR=0.96 (95% CI, 0.91–1.00) for second quartile; HR=0.92 (95%

Figure 1. Adjusted cumulative incidence of atrial fibrillation among remnant cholesterol quartile (Q) groups.

CI, 0.88–0.96) for third quartile; and HR=0.85 (95% CI, 0.81–0.89) for fourth quartile (*P* for trend <0.001). When treating RC as a continuous variable, per 0.26 mmol/L (10 mg/dL) increase in RC was significantly associated with a 4% lower risk of incident AF (HR=0.96 [95% CI, 0.95–0.97]) (Table S3). Restricted cubic spline analyses showed a linear and inverse relationship between RC and AF risk (*P* for nonlinearity=0.50) (Figure S3).

Figure 3 presents the subgroup analysis results for the association between RC quartiles and risk of incident AF. We found significant interactions by age, sex, and history of diabetes (*P*<0.001 for interaction). The association between RC quartiles and risk of incident

AF was stronger in participants aged ≥65 years, in men, and in participants without history of diabetes when compared with control groups.

Sensitivity analyses yielded similar findings to the main results for both RC quartile groups (Figure 4, Tables S4 and S5) and continuous RC levels (Table S3).

DISCUSSION

In this analysis based on data from the prospective UK Biobank study, we found that (1) the risk of incident AF was decreased with increased RC levels, with a 15%

RC quartiles	No. of events / participants		HR (95% CI)	P for trend
Q1	5082/ 105406		Ref	< 0.001
Q2	6118/ 105762		0.96 (0.91 – 1.00)	
Q3	6697/ 105611		0.92 (0.88 – 0.96)	
Q4	6877/ 105537		0.85 (0.81 – 0.89)	

0.8   0.9   1
The estimates

Figure 2. Association between remnant cholesterol (RC) quartiles (Qs) and risk of atrial fibrillation.
HR indicates hazard ratio; and Ref, reference.

lower risk for the fourth quartile when compared with first quartile group; and (2) the association between RC quartiles and AF risk was modified by participants' status, including age, sex, and history of diabetes. Results from sensitivity analyses supported the robustness of the main findings.

Previous studies have shown that higher levels of TC, LDL-C, and triglycerides were associated with lower AF risk.[10,11,15–20] For example, a Korean nationwide cohort study of 3 660 385 adults reported that the highest quartile of TC, LDL-C, and triglycerides had 22%, 19%, and 12% lower AF risk, respectively, compared with the lowest quartile.[11] Similarly, a prospective cohort study in China with 88 785 participants found that the highest quartile of TC and LDL-C had 40% lower AF risk compared with the lowest quartile.[18] Moreover, a recent systematic review and meta-analysis of >4 million participants reported a 5% lower AF risk per 1-mmol/L increase in baseline TC or LDL-C.[10] Furthermore, a meta-analysis of randomized controlled trials showed that omega-3 fatty acid supplementation was associated with a significantly increased risk for AF in patients with elevated plasma triglyceride and at high risk of cardiovascular disease when compared with placebo.[44] Our exploratory analysis showed participants in the highest quartile of LDL-C, triglycerides, and TC had a 10%, 16%, and 11% lower risk of incident AF than those in the lowest quartile, respectively (Table S6). In another analysis, we found participants in the upper quartiles of the LDL-C had a significantly lower cumulative incidence of AF compared with the lowest quartile (Figure S4). These results were in line with previous findings, providing further evidence for the cholesterol paradox.

However, evidence on the relationship between RC and risk of AF remains sparse. A recent study was based on data from a health claims database, which mainly involved young and middle-aged adults in Asia and reported an inverse relationship between RC and AF.[45] In our study, we included participants who were middle-aged or older from a multicenter prospective cohort in the United Kingdom, of whom 94.65% were

White race. Our results from a large sample size and a wealth of covariates were in agreement with the previous study. When we ran a post hoc analysis separated by Asian, White, and other race, similar relationship between RC and AF risk across these racial groups was demonstrated. Moreover, unlike the previous study, we followed up participants for a longer time (11.9 versus 3.0 years), and performed rigorous analyses, including multiple subgroup and sensitivity analyses. Therefore, our results could strengthen the inverse association between RC and AF risk.

A meta-analysis of both published and unpublished results from randomized controlled trials showed that statins do not increase the risk of AF.[46] Another systematic review of randomized controlled trials demonstrated a significant association between statin use and reduced incidence of AF among patients with a history of previous AF or undergoing cardiac surgery or after acute coronary syndrome.[47] This indicated that the relationship between RC and AF risk may be influenced by statins. However, our sensitivity analyses by further adjusting for statin use yielded similar findings to the main results (Table S5).

Previous studies demonstrated a positive association between elevated RC and the risk of atherosclerotic heart diseases.[24,26,27] However, our study revealed an inverse relationship between RC and AF risk, suggesting that part of the cause of AF is different from that of atherosclerotic heart diseases, and that a poor atherogenic to antiatherogenic balance may not be a fundamental mechanism for AF development. Further research is needed for elucidation.

We observed a stronger statistical relationship between RC and AF risk in participants aged ≥65 years. AF prevalence increases significantly with age,[48] whereas TC levels decrease as age increases.[49] Thus, lower TC levels in older groups (age ≥65 years) may partly account for the inverse association between RC levels and AF risk. The association between RC and risk of AF remained statistically significant for men, possibly because of their higher AF incidence and lower serum TC and triglyceride levels with age than

Subgroups	RC quartiles	No. of events / participants	HR (95% CI)	P for interaction
Age, years				< 0.001
<65	Q1	2993/ 90220	Ref	
	Q2	3479/ 85037	0.99 (0.94 – 1.06)	
	Q3	3787/ 82873	0.95 (0.90 – 1.01)	
	Q4	4235/ 84784	0.88 (0.83 – 0.93)	
≥65	Q1	2089/ 15186	Ref	
	Q2	2639/ 20725	0.86 (0.80 – 0.93)	
	Q3	2910/ 22738	0.83 (0.77 – 0.89)	
	Q4	2642/ 20753	0.76 (0.70 – 0.82)	
Sex				< 0.001
Women	Q1	2143/ 70618	Ref	
	Q2	2593/ 62690	1.05 (0.98 – 1.13)	
	Q3	2551/ 53828	1.06 (0.98 – 1.14)	
	Q4	2119/ 41771	1.01 (0.92 – 1.09)	
Men	Q1	2939/ 34788	Ref	
	Q2	3525/ 43072	0.88 (0.83 – 0.93)	
	Q3	4146/ 51783	0.82 (0.77 – 0.87)	
	Q4	4758/ 63766	0.75 (0.71 – 0.80)	
Ethnicity				0.081
White	Q1	4895/ 97764	Ref	
	Q2	5939/ 99871	0.95 (0.91 – 1.00)	
	Q3	6490/ 100108	0.91 (0.87 – 0.95)	
	Q4	6666/ 100075	0.84 (0.80 – 0.88)	
Non– white	Q1	157/ 7158	Ref	
	Q2	157/ 5399	1.07 (0.80 – 1.44)	
	Q3	169/ 5016	1.26 (0.94 – 1.68)	
	Q4	171/ 4934	1.09 (0.81 – 1.47)	
BMI, kg/m²				0.976
<25	Q1	2037/ 56540	Ref	
	Q2	1589/ 38858	1.00 (0.92 – 1.08)	
	Q3	1117/ 26166	0.92 (0.84 – 1.00)	
	Q4	663/ 15560	0.79 (0.71 – 0.88)	
≥25	Q1	3005/ 48464	Ref	
	Q2	4490/ 66533	0.93 (0.88 – 0.98)	
	Q3	5536/ 79005	0.90 (0.86 – 0.95)	
	Q4	6169/ 89511	0.84 (0.80 – 0.89)	
Smoking				0.135
No	Q1	2537/ 62922	Ref	
	Q2	2887/ 59480	0.95 (0.89 – 1.02)	
	Q3	2924/ 56101	0.93 (0.87 – 0.99)	
	Q4	2680/ 51812	0.80 (0.74 – 0.85)	
Yes	Q1	2524/ 42013	Ref	
	Q2	3198/ 45786	0.96 (0.90 – 1.02)	
	Q3	3719/ 48940	0.91 (0.85 – 0.97)	
	Q4	4128/ 53127	0.88 (0.83 – 0.94)	
Diabetes				< 0.001
No	Q1	4773/ 102076	Ref	
	Q2	5603/ 101515	0.95 (0.90 – 0.99)	
	Q3	5931/ 99416	0.91 (0.87 – 0.95)	
	Q4	5847/ 97929	0.82 (0.78 – 0.86)	
Yes	Q1	309/ 3330	Ref	
	Q2	515/ 4247	1.12 (0.93 – 1.33)	
	Q3	766/ 6195	1.05 (0.89 – 1.24)	
	Q4	1030/ 7608	1.13 (0.96 – 1.33)	
Hypertension				0.116
No	Q1	3050/ 85731	Ref	
	Q2	3336/ 79239	0.96 (0.91 – 1.02)	
	Q3	3316/ 73237	0.92 (0.87 – 0.98)	
	Q4	3209/ 69690	0.86 (0.80 – 0.91)	
Yes	Q1	2032/ 19675	Ref	
	Q2	2782/ 26523	0.92 (0.85 – 0.99)	
	Q3	3381/ 32374	0.88 (0.82 – 0.94)	
	Q4	3668/ 35847	0.81 (0.75 – 0.86)	
CAD				0.825
No	Q1	4533/ 102257	Ref	
	Q2	5407/ 101609	0.96 (0.91 – 1.01)	
	Q3	5814/ 100673	0.91 (0.87 – 0.96)	
	Q4	5924/ 100103	0.84 (0.80 – 0.88)	
Yes	Q1	549/ 3149	Ref	
	Q2	711/ 4153	0.91 (0.79 – 1.04)	
	Q3	883/ 4938	0.92 (0.80 – 1.05)	
	Q4	953/ 5434	0.86 (0.75 – 0.98)	
HF				0.224
No	Q1	5032/ 105196	Ref	
	Q2	6043/ 105467	0.95 (0.91 – 1.00)	
	Q3	6605/ 105267	0.91 (0.87 – 0.96)	
	Q4	6758/ 105072	0.84 (0.81 – 0.88)	
Yes	Q1	50/ 210	Ref	
	Q2	75/ 295	1.02 (0.64 – 1.62)	
	Q3	92/ 344	1.12 (0.72 – 1.75)	
	Q4	119/ 465	1.07 (0.69 – 1.66)	
Statin use				0.165
No	Q1	3742/ 93816	Ref	
	Q2	4279/ 90136	0.95 (0.90 – 1.01)	
	Q3	4475/ 86396	0.92 (0.87 – 0.97)	
	Q4	4493/ 84736	0.83 (0.78 – 0.87)	
Yes	Q1	1340/ 11590	Ref	
	Q2	1839/ 15626	0.92 (0.84 – 1.00)	
	Q3	2222/ 19215	0.87 (0.80 – 0.94)	
	Q4	2384/ 20801	0.83 (0.77 – 0.91)	
LDL–C, mmol/L				0.745
<2.6	Q1	1467/ 21873	Ref	
	Q2	1553/ 16787	0.96 (0.88 – 1.05)	
	Q3	1773/ 17282	0.94 (0.87 – 1.03)	
	Q4	2029/ 19457	0.87 (0.80 – 0.95)	
≥2.6	Q1	3615/ 83533	Ref	
	Q2	4565/ 88975	0.95 (0.90 – 1.01)	
	Q3	4924/ 88329	0.91 (0.86 – 0.96)	
	Q4	4848/ 86080	0.84 (0.79 – 0.88)	

0.5   1   1.5
The estimates

Figure 3. Subgroup analyses results for the association between remnant cholesterol (RC) quartiles (Qs) and risk of atrial fibrillation.
BMI indicates body mass index; CAD, coronary artery disease; HF, heart failure; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol; and Ref, reference. Non-White includes Black, Asian, Mixed, and Other.

Figure 4. Sensitivity analyses results for the association between remnant cholesterol (RC) quartiles (Qs) and risk of atrial fibrillation (AF).
HR indicates hazard ratio; POAF, postoperative AF; and Ref, reference.

women.[50,51] Moreover, the electrophysiological properties of the atria differ between men and women.[52] The association between RC and AF risk was not statistically significant among participants with a history of diabetes. This could be attributed to the fact that diabetes is an independent risk factor for AF,[53] and that RC levels are markedly higher in patients with diabetes.[54] However, our observational study was of an exploratory nature, and thus results should be cautiously interpreted. Further studies are warranted to examine the association between RC and risk of AF.

Strengths and Limitations

Our study has several strengths, such as using data from 1 of the largest prospective cohorts worldwide, having a large amount of information available in the cohort, and performing rigorous methods and detailed analyses that supported the validity of our results.

However, we also acknowledge several potential limitations. First, as an observational study, we could not fully preclude confounding and reverse causation between RC and AF. Even after extensive adjustment, there could be residual confounding, especially those that were unmeasured.[55,56] Second, the ascertainment of AF events made by physicians from different hospitals across the country may yield misdiagnosis and undiagnosis to an unknown extent. Likewise, there may be heterogeneity in *ICD-9* or *ICD-10* code assignment. Additionally, because disease *ICD-9* and *ICD-10* codes were sometimes assigned when a disease was suspected before further diagnostic testing, it was unclear whether a given *ICD-9* or *ICD-10* code referred to the final diagnosis.[57] However, identification of AF from electronic medical data had been reported to have a good positive predictive value of 89%.[58] Third, we estimated RC using nonfasting TC minus HDL-C and LDL-C, as previously applied,[23,25,26] which may differ from the direct measurement of RC.[59] However, calculated RC and measured RC are highly correlated,[60,61] and the calculation of RC is an affordable and accessible method in clinical practice. Fourth, we could not account for temporal changes in RC because of data unavailability. RC was estimated only at baseline and may change over time, which could affect the subsequent risk of AF. Fifth, we used baseline values in our statistical models, and could not account for the change in known risk factors for AF (eg, incidence or changes in hypertension, obesity, HF, or CAD) over time. Finally, our findings may not be generalizable to populations with comorbidities, because of the relatively healthy participants in the UK Biobank.[62] Therefore, our results should be interpreted with caution and require more evidence to further elucidate the relationship between RC and AF risk.

CONCLUSIONS

On the basis of data from this large-scale prospective cohort study, elevated RC was associated with a lower risk of incident AF, especially in participants who were aged ≥65 years, men, and those without history of diabetes.

ARTICLE INFORMATION

Affiliations

Center for Clinical Epidemiology and Methodology, Guangdong Second Provincial General Hospital, Guangzhou, China (L.L., J.Z., G.L.); National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (C.W.); Department of Cardiology, Guangdong Second Provincial General Hospital, Guangzhou, China (Z.Y.); Department of Medicine, McMaster University, Hamilton, ON, Canada (H.G.V.S.); Population Health Research Institute, McMaster University, Hamilton, ON, Canada (H.G.V.S.); Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, UK (G.Y.L.); Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark (G.Y.L.); and Father Sean O'Sullivan Research Centre, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada (G.L.).

Supplemental Material

Tables S1–S6
Figures S1–S4

REFERENCES

1. Frederiksen TC, Dahm CC, Preis SR, Lin H, Trinquart L, Benjamin EJ, Kornej J. The bidirectional association between atrial fibrillation and myocardial infarction. *Nat Rev Cardiol*. 2023;20:631–644. doi: 10.1038/s41569-023-00857-3
2. Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes. *Circ Res*. 2017;120:1501–1517. doi: 10.1161/CIRCRESAHA.117.309732
3. Yiin GS, Howard DP, Paul NL, Li L, Luengo-Fernandez R, Bull LM, Welch SJ, Gutnikov SA, Mehta Z, Rothwell PM, et al. Age-specific incidence, outcome, cost, and projected future burden of atrial fibrillation-related embolic vascular events: a population-based study. *Circulation*. 2014;130:1236–1244. doi: 10.1161/CIRCULATIONAHA.114.010942
4. Magnani JW, Rienstra M, Lin H, Sinner MF, Lubitz SA, McManus DD, Dupuis J, Ellinor PT, Benjamin EJ. Atrial fibrillation: current knowledge and future directions in epidemiology and genomics. *Circulation*. 2011;124:1982–1993. doi: 10.1161/CIRCULATIONAHA.111.039677
5. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D'Agostino RB Sr, Newton-Cheh C, Yamamoto JF, Magnani JW, Tadros TM, et al. Development of a risk score for atrial fibrillation (Framingham heart study): a community-based cohort study. *Lancet*. 2009;373:739–745. doi: 10.1016/S0140-6736(09)60443-8
6. Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, Maclehose R, Konety S, Alonso A. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the atherosclerosis risk in communities (ARIC) study. *Circulation*. 2011;123:1501–1508. doi: 10.1161/CIRCULATIONAHA.110.009035
7. Du Z, Qin Y. Dyslipidemia and cardiovascular disease: current knowledge, existing challenges, and new opportunities for management strategies. *J Clin Med*. 2023;12:12. doi: 10.3390/jcm12010363
8. Ding WY, Protty MB, Davies IG, Lip GYH. Relationship between lipoproteins, thrombosis, and atrial fibrillation. *Cardiovasc Res*. 2022;118:716–731. doi: 10.1093/cvr/cvab017
9. Sagris D, Harrison SL, Lip GYH. Lipids and atrial fibrillation: new insights into a paradox. *PLoS Med*. 2022;19:e1004067. doi: 10.1371/journal.pmed.1004067
10. Yao Y, Liu F, Wang Y, Liu Z. Lipid levels and risk of new-onset atrial fibrillation: a systematic review and dose-response meta-analysis. *Clin Cardiol*. 2020;43:935–943. doi: 10.1002/clc.23430

11. Lee HJ, Lee SR, Choi EK, Han KD, Oh S. Low lipid levels and high variability are associated with the risk of new-onset atrial fibrillation. *J Am Heart Assoc*. 2019;8:e012771. doi: 10.1161/JAHA.119.012771

12. Trieb M, Kornej J, Knuplez E, Hindricks G, Thiele H, Sommer P, Scharnagl H, Dagres N, Dinov B, Bollmann A, et al. Atrial fibrillation is associated with alterations in HDL function, metabolism, and particle number. *Basic Res Cardiol*. 2019;114:27. doi: 10.1007/s00395-019-0735-0

13. Alonso A, Yin X, Roetker NS, Magnani JW, Kronmal RA, Ellinor PT, Chen LY, Lubitz SA, McClelland RL, McManus DD, et al. Blood lipids and the incidence of atrial fibrillation: the multi-ethnic study of atherosclerosis and the Framingham heart study. *J Am Heart Assoc*. 2014;3:e001211. doi: 10.1161/JAHA.114.001211

14. Knuiman M, Briffa T, Divitini M, Chew D, Eikelboom J, McQuillan B, Hung J. A cohort study examination of established and emerging risk factors for atrial fibrillation: the Busselton health study. *Eur J Epidemiol*. 2014;29:181–190. doi: 10.1007/s10654-013-9875-y

15. Tajik B, Tuomainen TP, Jarroch R, Kauhanen J, Lip GYH, Isanejad M. Lipid levels, apolipoproteins, and risk of incident atrial fibrillation in men: a report from the Kuopio Ischaemic heart disease risk factor study (KIHD). *J Clin Lipidol*. 2022;16:447–454. doi: 10.1016/j.jacl.2022.04.003

16. Xue Y, Zhou Q, Shen J, Liu G, Zhou W, Wen Y, Luo S. Lipid profile and new-onset atrial fibrillation in patients with acute ST-segment elevation myocardial infarction (an observational study in southwest of China). *Am J Cardiol*. 2019;124:1512–1517. doi: 10.1016/j.amjcard.2019.07.070

17. Mourtzinis G, Kahan T, Bengtsson Bostrom K, Schioler L, Cedstrand Wallin L, Hjerpe P, Hasselstrom J, Manhem K. Relation between lipid profile and new-onset atrial fibrillation in patients with systemic hypertension (from the Swedish primary care cardiovascular database [SPCCD]). *Am J Cardiol*. 2018;122:102–107. doi: 10.1016/j.amjcard.2018.03.024

18. Li X, Gao L, Wang Z, Guan B, Guan X, Wang B, Han X, Xiao X, Waleed KB, Chandran C, et al. Lipid profile and incidence of atrial fibrillation: a prospective cohort study in China. *Clin Cardiol*. 2018;41:314–320. doi: 10.1002/clc.22864

19. Magnussen C, Niiranen TJ, Ojeda FM, Gianfagna F, Blankenberg S, Njolstad I, Vartiainen E, Sans S, Pasterkamp G, Hughes M, et al. Sex differences and similarities in atrial fibrillation epidemiology, risk factors, and mortality in community cohorts: results from the BiomarCaRE consortium (biomarker for cardiovascular risk assessment in Europe). *Circulation*. 2017;136:1588–1597. doi: 10.1161/CIRCULATIONAHA.117.028981

20. Lopez FL, Agarwal SK, Maclehose RF, Soliman EZ, Sharrett AR, Huxley RR, Konety S, Ballantyne CM, Alonso A. Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: the atherosclerosis risk in communities study. *Circ Arrhythm Electrophysiol*. 2012;5:155–162. doi: 10.1161/CIRCEP.111.966804

21. Sturzebecher PE, Katzmann JL, Laufs U. What is 'remnant cholesterol'? *Eur Heart J*. 2023;44:1446–1448. doi: 10.1093/eurheartj/ehac783

22. Wang R, Gerstein HC, Van Spall HGC, Lip GYH, Olier I, Ortega-Martorell S, Thabane L, Ye Z, Li G. Relationship between remnant cholesterol and risk of heart failure in participants with diabetes mellitus. *Eur Heart J Qual Care Clin Outcomes*. 2023;9:537–545. doi: 10.1093/ehjqcco/qcad030

23. Wadstrom BN, Pedersen KM, Wulff AB, Nordestgaard BG. Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality. *Eur Heart J*. 2023;44:1432–1445. doi: 10.1093/eurheartj/ehac822

24. Yang XH, Zhang BL, Cheng Y, Fu SK, Jin HM. Association of remnant cholesterol with risk of cardiovascular disease events, stroke, and mortality: a systemic review and meta-analysis. *Atherosclerosis*. 2023;371:21–31. doi: 10.1016/j.atherosclerosis.2023.03.012

25. Wadstrom BN, Wulff AB, Pedersen KM, Jensen GB, Nordestgaard BG. Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study. *Eur Heart J*. 2022;43:3258–3269. doi: 10.1093/eurheartj/ehab705

26. Quispe R, Martin SS, Michos ED, Lamba I, Blumenthal RS, Saeed A, Lima J, Puri R, Nomura S, Tsai M, et al. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. *Eur Heart J*. 2021;42:4324–4332. doi: 10.1093/eurheartj/ehab432

27. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. *Lancet*. 2014;384:626–635. doi: 10.1016/S0140-6736(14)61177-6

28. Liang F, Wang Y. Coronary heart disease and atrial fibrillation: a vicious cycle. *Am J Physiol Heart Circ Physiol*. 2021;320:H1–H12. doi: 10.1152/ajpheart.00702.2020

29. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Rooij FJ, Lip GY, Witteman JC. Subclinical atherosclerosis and risk of atrial fibrillation: the rotterdam study. *Arch Intern Med*. 2007;167:382–387. doi: 10.1001/archinte.167.4.382

30. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray M, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med*. 2015;12:e1001779. doi: 10.1371/journal.pmed.1001779

31. Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. *Commun Stat-Simul Comput*. 2009;38:1228–1234. doi: 10.1080/03610910902859574

32. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. *Multivar Behav Res*. 2011;46:399–424. doi: 10.1080/00273171.2011.568786

33. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J*. 2020;41:111–188. doi: 10.1093/eurheartj/ehz455

34. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem*. 1972;18:499–502. doi: 10.1093/clinchem/18.6.499

35. Castaner O, Pinto X, Subirana I, Amor AJ, Ros E, Hernaez A, Martinez-Gonzalez MA, Corella D, Salas-Salvado J, Estruch R, et al. Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease. *J Am Coll Cardiol*. 2020;76:2712–2724. doi: 10.1016/j.jacc.2020.10.008

36. group Sw, collaboration ESCCr. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. *Eur Heart J*. 2021;42:2439–2454. doi: 10.1093/eurheartj/ehab309

37. group SOw, collaboration ESCCr. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. *Eur Heart J*. 2021;42:2455–2467. doi: 10.1093/eurheartj/ehab312

38. Berry. G, Armitage. P. Mid-p confidence intervals: a brief review. *J Roy Stat Soc Ser D* 1995;44:417–423. doi: 10.2307/2348891

39. Al-Shaar L, Satija A, Wang DD, Rimm EB, Smith-Warner SA, Stampfer MJ, Hu FB, Willett WC. Red meat intake and risk of coronary heart disease among US men: prospective cohort study. *BMJ*. 2020;371:m4141. doi: 10.1136/bmj.m4141

40. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. *JAMA*. 2003;290:2945–2951. doi: 10.1001/jama.290.22.2945

41. Zhang Y, Guallar E, Ashar FN, Longchamps RJ, Castellani CA, Lane J, Grove ML, Coresh J, Sotoodehnia N, Ilkhanoff L, et al. Association between mitochondrial DNA copy number and sudden cardiac death: findings from the atherosclerosis risk in communities study (ARIC). *Eur Heart J*. 2017;38:3443–3448. doi: 10.1093/eurheartj/ehx354

42. Daniel RM, Cousens SN, De Stavola BL, Kenward MG, Sterne JA. Methods for dealing with time-dependent confounding. *Stat Med*. 2013;32:1584–1618. doi: 10.1002/sim.5686

43. Schomaker M, Davies MA, Malateste K, Renner L, Sawry S, N'Gbeche S, Technau KG, Eboua F, Tanser F, Sygnate-Sy H, et al. Growth and mortality outcomes for different antiretroviral therapy initiation criteria in children ages 1-5 years: a causal modeling analysis. *Epidemiology*. 2016;27:237–246. doi: 10.1097/EDE.0000000000000412

44. Lombardi M, Carbone S, Del Buono MG, Chiabrando JG, Vescovo GM, Camilli M, Montone RA, Vergallo R, Abbate A, Biondi-Zoccai G, et al. Omega-3 fatty acids supplementation and risk of atrial fibrillation: an updated meta-analysis of randomized controlled trials. *Eur Heart J Cardiovasc Pharmacother*. 2021;7:e69–e70. doi: 10.1093/ehjcvp/pvab008

45. Tada H, Kaneko H, Suzuki Y, Okada A, Takeda N, Fujiu K, Morita H, Ako J, Node K, Takeji Y, et al. Association between remnant cholesterol and incident atherosclerotic cardiovascular disease, heart failure, and atrial fibrillation. *J Clin Lipidol*. 2023;18:3–10. doi: 10.1016/j.jacl.2023.10.006

46. Rahimi K, Emberson J, McGale P, Majoni W, Merhi A, Asselbergs FW, Krane V, Macfarlane PW, Executive P. Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. *BMJ*. 2011;342:d1250. doi: 10.1136/bmj.d1250

47. Fauchier L, Pierre B, de Labriolle A, Grimard C, Zannad N, Babuty D. Antiarrhythmic effect of statin therapy and atrial fibrillation a

meta-analysis of randomized controlled trials. *J Am Coll Cardiol.* 2008;51:828–835. doi: 10.1016/j.jacc.2007.09.063

48. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. *Clin Epidemiol.* 2014;6:213–220. doi: 10.2147/CLEP.S47385

49. Jacobs JM, Cohen A, Ein-Mor E, Stessman J. Cholesterol, statins, and longevity from age 70 to 90 years. *J Am Med Dir Assoc.* 2013;14:883–888. doi: 10.1016/j.jamda.2013.08.012

50. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, Newton-Cheh C, Lubitz SA, Magnani JW, Ellinor PT, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham heart study: a cohort study. *Lancet.* 2015;386:154–162. doi: 10.1016/S0140-6736(14)61774-8

51. Godsland IF, Wynn V, Crook D, Miller NE. Sex, plasma lipoproteins, and atherosclerosis: prevailing assumptions and outstanding questions. *Am Heart J.* 1987;114:1467–1503. doi: 10.1016/0002-8703(87)90552-7

52. Tse HF, Oral H, Pelosi F, Knight BP, Strickberger SA, Morady F. Effect of gender on atrial electrophysiologic changes induced by rapid atrial pacing and elevation of atrial pressure. *J Cardiovasc Electrophysiol.* 2001;12:986–989. doi: 10.1046/j.1540-8167.2001.00986.x

53. Wang A, Green JB, Halperin JL, Piccini JP Sr. Atrial fibrillation and diabetes mellitus: JACC review topic of the week. *J Am Coll Cardiol.* 2019;74:1107–1115. doi: 10.1016/j.jacc.2019.07.020

54. Wadstrom BN, Pedersen KM, Wulff AB, Nordestgaard BG. Elevated remnant cholesterol and atherosclerotic cardiovascular disease in diabetes: a population-based prospective cohort study. *Diabetologia.* 2023;66:2238–2249. doi: 10.1007/s00125-023-06016-0

55. Au Yeung SL, Luo S, Schooling CM. The impact of glycated hemoglobin (HbA(1c)) on cardiovascular disease risk: a Mendelian randomization study using UK biobank. *Diabetes Care.* 2018;41:1991–1997. doi: 10.2337/dc18-0289

56. Li G, Holbrook A, Jin Y, Zhang Y, Levine MA, Mbuagbaw L, Witt DM, Crowther M, Connolly S, Chai-Adisaksopha C, et al. Comparison of treatment effect estimates of non-vitamin K antagonist oral anticoagulants versus warfarin between observational studies using propensity score methods and randomized controlled trials. *Eur J Epidemiol.* 2016;31:541–561. doi: 10.1007/s10654-016-0178-y

57. Ritchie MD, Denny JC, Crawford DC, Ramirez AH, Weiner JB, Pulley JM, Basford MA, Brown-Gentry K, Balser JR, Masys DR, et al. Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. *Am J Hum Genet.* 2010;86:560–572. doi: 10.1016/j.ajhg.2010.03.003

58. Jensen PN, Johnson K, Floyd J, Heckbert SR, Carnahan R, Dublin S. A systematic review of validated methods for identifying atrial fibrillation using administrative data. *Pharmacoepidemiol Drug Saf.* 2012;21(Suppl 1):141–147. doi: 10.1002/pds.2317

59. Chen J, Kuang J, Tang X, Mao L, Guo X, Luo Q, Peng D, Yu B. Comparison of calculated remnant lipoprotein cholesterol levels with levels directly measured by nuclear magnetic resonance. *Lipids Health Dis.* 2020;19:132. doi: 10.1186/s12944-020-01311-w

60. Varbo A, Nordestgaard BG. Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction. *Eur Heart J.* 2021;42:4833–4843. doi: 10.1093/eurheartj/ehab293

61. Duran EK, Aday AW, Cook NR, Buring JE, Ridker PM, Pradhan AD. Triglyceride-rich lipoprotein cholesterol, small dense LDL cholesterol, and incident cardiovascular disease. *J Am Coll Cardiol.* 2020;75:2122–2135. doi: 10.1016/j.jacc.2020.02.059

62. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, Collins R, Allen NE. Comparison of sociodemographic and health-related characteristics of UK biobank participants with those of the general population. *Am J Epidemiol.* 2017;186:1026–1034. doi: 10.1093/aje/kwx246